Skip to main content
MADRIGAL PHARMACEUTICALS, INC. logo

MADRIGAL PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · MDGL ISIN · US5588681057 LEI · 549300CHIMT2EUSNJB60 US Manufacturing
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2021-06-21 Director's Dealing
Country US United States of America
Listing US MDGL

About MADRIGAL PHARMACEUTICALS, INC.

https://www.madrigalpharma.com/

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious and progressive liver disease with high unmet medical need. The company's research led to the first U.S. Food and Drug Administration (FDA)-approved treatment for MASH. Madrigal's therapeutic goal is to halt or reverse liver scarring (fibrosis) and resolve the disease before patients experience severe complications, including cirrhosis, liver failure, and the need for transplantation.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-06-21 English
FORM 4 SUBMISSION
Director's Dealing
2021-06-21 English
FORM 4 SUBMISSION
Director's Dealing
2021-06-21 English
FORM 4 SUBMISSION
Director's Dealing
2021-06-21 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a Sales Agreement for an 'at the market' offering of common stock. There are no financial statements or detailed financial data presented, only the announcement of the agreement and related exhibits. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length is 5582 characters, sufficient for a detailed announcement but not a full financial report. Therefore, the correct classification is CAP with high confidence.
2021-06-01 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It includes details about a shelf registration for a common stock offering up to $200 million, with information about the sales agreement, underwriting fees, risk factors, use of proceeds, and other offering details. The document is a registration statement amendment related to a securities offering, not a financial report, earnings release, or management discussion. It is a detailed offering document used to raise capital through equity issuance. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and financing activities. The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication announcement but a substantive financing document.
2021-06-01 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.